Pediatrix Medical Group and MEDNAX are the largest network of neonatologists, pediatric hospitalists and advanced practice providers in the United States, caring for nearly 25% of neonatal patients. We continue to execute many changes at Natus that we expect to result in sustainable payoffs to our stakeholders in the quarters and years ahead.I'd now like to briefly describe the recently announced transition of our Peloton hearing screening service business to Pediatrix. In addition to our year-to-date achievements, we continue to make progress further integrating our supply chain and operations. During the quarter, we added to this progress and our margins and cash flow are evidence of that. Only nine months ago, we announced our One Natus initiative.The results of this effort have better positioned us for growth, increase our product quality and made us a more efficient company. Drew will discuss working capital and cash flow in more detail in just a few minutes. As we've discussed before, our capital-light business has a tremendous ability to generate cash, and we look forward to further improvements in cash flow. During the quarter, we continued to execute our strategic plan of focusing our efforts in the central nervous system and sensory systems markets and achieved significant improvements in operation efficiency.In addition to the outstanding cash flow generation during the quarter, we reduced our long-term debt by $10 million. Overall, we achieved organic revenue growth of 2% after adjusting for divestitures and discontinued products.

We expect these changes to be implemented by early next year. After adjusting for divestitures, revenue from our neuro end-market grew 8% for the second quarter in a row with all major neuro submarkets making positive contributions to neuro's growth, including neurosurgery.Our newborn care and hearing and balance markets were down year-over-year but showed growth in phototherapy, vision screening and hearing fitting submarkets.The negative trend was driven primarily by voluntary ship holds in order to address certain product design changes. Our performance in the quarter drove a significant increase in cash flow, achieving $23.9 million in cash flow from operations. Both were in line with our previous expectations.Our third quarter results demonstrate the continued improvement in our business.

Revenue for the quarter was $123.5 million and non-GAAP earnings per share was $0.36. Today, we reported the results for the third quarter of 2019. Jonathan Kennedy: Thank you, operator, and good afternoon, everyone.I would now like to turn the call over to Jonathan Kennedy, President and Chief Executive Officer of Natus Medical. Our actual results may differ materially from these forward-looking statements.For a description of relevant risks and uncertainties pertaining to our business, please see today's press release and our periodic and annual reports filed with the SEC. These statements include management's beliefs and expectations about our future results. Today's call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Then, Drew will discuss the third quarter financial performance and provide guidance for the fourth quarter and full-year 2019.Finally, we will open the call for your questions. Jonathan will begin today with a business overview of the third quarter 2019. On the call today from Natus is Jonathan Kennedy, Natus' President and Chief Executive Officer and Drew Davies, Natus' Executive Vice President and Chief Financial Officer. Operator: Good afternoon, everyone, and thank you for joining us today to review our results for the Third Quarter of 2019.

Natus peloton